La vendita allo scoperto per InfuSystems Holdings dà agli investitori un'idea del grado in cui gli investitori stanno scommettendo sul declino delle azioni di InfuSystems Holdings. I dati relativi alle vendite allo scoperto vengono aggiornati ogni due settimane.

InfuSystems Holdings (AMEX:INFU) Azioni, Report sulle vendite allo scoperto

InfuSystems Holdings

InfuSystems Holdings Inc is a health care service provider, facilitating outpatient care for durable medical equipment manufacturers and health care providers. INFU services are provided under a two-reportable segment. The first is Patient Services, providing the last-mile solution for clinic-to-home healthcare where the continuing treatment involves complex durable medical equipment and services. The Patient segment is comprised of Oncology, Pain Management and Wound Therapy businesses. The second, Device Solutions, supports the Patient Services platform and leverages service orientation to win incremental business from its direct payer clients. The Device segment is comprised of direct payer rentals, pump and consumable sales, and biomedical services and repair. Majority from Patient.

InfuSystems Holdings Inc

INFUSION BRANDS INTL INC by Infusion Brands International, Inc.

Infusion Brands International Inc

InfuSystems Holdings (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/INFU#AMEX">INFU</a>) affirms FY2025 sales outlook from $145.65 million-$148.35 million to $145.65 million-$148.35 million vs $146.63 million estimate.

News

Guidance

INFU

InfuSystems Holdings Affirms FY2025 Sales Guidance of $145.65M-$148.35M vs $146.63M Est

InfuSystems Holdings (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/INFU#AMEX">INFU</a>) reported quarterly losses of $(0.01) per share which beat the analyst consensus estimate of $(0.04) by 75 percent. This is a 80 percent increase over losses of $(0.05) per share from the same period last year. The company reported quarterly sales of $34.72 million which beat the analyst consensus estimate of $33.70 million by 3.01 percent. This is a 8.50 percent increase over sales of $32.00 million the same period last year.

Earnings

Earnings Beats

InfuSystems Holdings Q1 EPS $(0.01) Beats $(0.04) Estimate, Sales $34.72M Beat $33.70M Estimate

AAOI

ABCL

ABEV

ACIC

ACIW

ACMR

ACTG

AFRM

AKAM

AKBA

ALGM

ALIT

ALRM

ALXO

Amplify YieldShares Oil Hedged MLP Income ETF

AMLX

AMPX

AMTX

APPN

APYX

AQMS

ARGX

ARHS

ARKO

ARLO

ASPN

ASTH

Adtalem Global Education Inc. Common Stock

ATGE

ATHM

ATUS

AUTL

AVAH

AVPT

AXGN

BAER

BBDC

BIGC

BILL

BIRD

BlackSky Technology Inc. Class A Common Stock

BKSY

BLFS

BLND

CARG

CARS

CBLL

CBUS

CCEC

CCOI

CCRD

CDTX

CION

CLAR

CLFD

CLNE

CLSK

CMPS

CMRE

CODX

COIN

COLD

COLL

COMP

CRNX

CRON

CROX

CRVS

CTEV

CTKB

CTLP

CVRX

DAVE

DCGO

DCTH

DIOD

DKNG

Earnings Scheduled For May 8, 2025

InfuSystems Holdings (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/INFU#AMEX">INFU</a>) will release its quarterly earnings report on Thursday, 2025-05-08. Here's a brief overview for investors ahead of the announcement.
Analysts anticipate InfuSystems Holdings to report an earnings per share (EPS) of $-0.03.
Investors in InfuSystems Holdings are eagerly awaiting the company's announcement, hoping for news of surpassing estimates and positive guidance for the next quarter.
It's worth noting for new investors that stock prices can be heavily influenced by future projections rather than just past performance.
<h3>Overview of Past Earnings</h3>
In the previous earnings release, the company missed EPS by $0.02, leading to a 3.71% drop in the share price the following trading session.
Here's a look at InfuSystems Holdings's past performance and the resulting price change:

<table>
<thead>
<tr>
<th>Quarter</th>
<th>Q4 2024</th>
<th>Q3 2024</th>
<th>Q2 2024</th>
<th>Q1 2024</th>
</tr>
</thead>
<tbody>
<tr>
<td>EPS Estimate</td>
<td>0.06</td>
<td>0.06</td>
<td>0.04</td>
<td>0.02</td>
</tr>
<tr>
<td>EPS Actual</td>
<td>0.04</td>
<td>0.08</td>
<td>0.03</td>
<td>-0.05</td>
</tr>
<tr>
<td>Price Change %</td>
<td>-4.0%</td>
<td>6.0%</td>
<td>0.0%</td>
<td>-4.0%</td>
</tr>
</tbody>
</table>

<img src="https://www.benzinga.com/files/images/story/2025/1746637750_0.png" alt="eps graph" />
<h3>InfuSystems Holdings Share Price Analysis</h3>
Shares of InfuSystems Holdings were trading at $4.7 as of May 06. Over the last 52-week period, shares are down 36.37%. Given that these returns are generally negative, long-term shareholders are likely bearish going into this earnings release. 
<a href="https://www.benzinga.com/quote/INFU/earnings">To track all earnings releases for InfuSystems Holdings visit their earnings calendar on our site.</a>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

InfuSystems Holdings's Earnings Outlook

Management

InfuSystem Appoints Carrie Lachance As CEO Effective May 19

A large exercise of company stock options by Richard Dilorio, Chief Executive Officer at InfuSystems Holdings (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/INFU#AMEX">INFU</a>) was disclosed in a new SEC filing on March 11, as part of an insider exercise.
What Happened: A Form 4 filing with the <a href="https://www.sec.gov/Archives/edgar/data/0001337013/000162828025012164//Archives/edgar/data/1337013/000162828025012164/0001628280-25-012164-index.htm">U.S. Securities and Exchange Commission</a> on Tuesday revealed that Dilorio, Chief Executive Officer at InfuSystems Holdings in the Health Care sector, exercised stock options for 25,000 shares of INFU stock. The exercise price of the options was $2.6 per share.
The latest update on Wednesday morning shows InfuSystems Holdings shares down by 0.45%, trading at $5.54. At this price, Dilorio's 25,000 shares are worth $73,625.
<h3>About InfuSystems Holdings</h3>
InfuSystems Holdings Inc is a health care service provider, facilitating outpatient care for durable medical equipment manufacturers and health care providers. INFU services are provided under a two-platform model. The first platform is Patient Services, providing the last-mile solution for clinic-to-home healthcare where the continuing treatment involves complex durable medical equipment and services. The Patient segment is comprised of Oncology, Pain Management and Wound Therapy businesses. The second platform, Device Solutions, supports the Patient Services platform and leverages strong service orientation to win incremental business from its direct payer clients. The Device segment is comprised of direct payer rentals, pump and consumable sales, and biomedical services and repair.
<h3>InfuSystems Holdings's Economic Impact: An Analysis</h3>
Decline in Revenue: Over the 3 months period, InfuSystems Holdings faced challenges, resulting in a decline of approximately -4.17% in revenue growth as of 31 December, 2024. This signifies a reduction in the company's top-line earnings. In comparison to its industry peers, the company trails behind with a growth rate lower than the average among peers in the Health Care sector.
Profitability Metrics: Unlocking Value
<ul>
<li>
Gross Margin: With a high gross margin of 53.82%, the company demonstrates effective cost control and strong profitability relative to its peers.
</li>
<li>
Earnings per Share (EPS): InfuSystems Holdings's EPS lags behind the industry average, indicating concerns and potential challenges with a current EPS of 0.04.
</li>
</ul>
Debt Management: InfuSystems Holdings's debt-to-equity ratio is below industry norms, indicating a sound financial structure with a ratio of 0.49.
Financial Valuation Breakdown:
<ul>
<li>
Price to Earnings (P/E) Ratio: InfuSystems Holdings's P/E ratio of 50.64 is below the industry average, suggesting the stock may be undervalued.
</li>
<li>
Price to Sales (P/S) Ratio: The current P/S ratio of 0.9 is below industry norms, suggesting potential undervaluation and presenting an investment opportunity for those considering sales performance.
</li>
<li>
EV/EBITDA Analysis (Enterprise Value to its Earnings Before Interest, Taxes, Depreciation &amp; Amortization): At 7.57, InfuSystems Holdings's EV/EBITDA ratio reflects a below-par valuation compared to industry averages signalling undervaluation
</li>
</ul>
Market Capitalization Analysis: Reflecting a smaller scale, the company's market capitalization is positioned below industry averages. This could be attributed to factors such as growth expectations or operational capacity.
<a href="https://www.schwab.com/brokerage?aff=XEC">Now trade stocks online commission free with Charles Schwab, a trusted and complete investment firm.</a>
<h3>The Relevance of Insider Transactions</h3>
Insightful as they may be, insider transactions should be considered alongside a thorough examination of other investment criteria.
Considering the legal perspective, an "insider" is defined as any officer, director, or beneficial owner holding more than ten percent of a company's equity securities, according to Section 12 of the Securities Exchange Act of 1934. This includes executives in the c-suite and major hedge funds. These insiders are mandated to disclose their transactions through a Form 4 filing, to be submitted within two business days of the transaction.
Pointing towards optimism, a company insider's new purchase signals their positive anticipation for the stock to rise.
Nevertheless, insider sells may not necessarily indicate a bearish view and can be influenced by various factors.
<h3>Cracking Transaction Codes</h3>
Surveying the realm of stock transactions, <a href="https://www.benzinga.com/money/investing-tools">investors</a> often give prominence to those unfolding in the open market, systematically detailed in Table I of the Form 4 filing. A P in Box 3 indicates a purchase, while S signifies a sale. Transaction code C denotes the conversion of an option, and transaction code A denotes a grant, award, or other acquisition of securities from the company.
<a href="https://www.benzinga.com/sec/insider-trades/search/index?company_cik=0001337013">Check Out The Full List Of InfuSystems Holdings's Insider Trades.</a>
Insider Buying Alert: Profit from C-Suite Moves
Benzinga Edge reveals every insider trade in real-time. Don't miss the next big stock move driven by insider confidence. Unlock this ultimate sentiment indicator now. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=Be8be9arja3be22in8&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Click here for access</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Insider Trades

Trading Ideas

Options Exercise: Richard Dilorio At InfuSystems Holdings Realizes $73K

InfuSystem is providing annual guidance for the full year 2025 with net revenue growth estimated to be in the 8% to 10% range. We are also forecasting Adjusted EBITDA margin (non-GAAP) to be in the high-teens, exceeding the Company's margin of 18.8% in 2024, this despite the planned continued investment in the Company's information technology systems. The Company intends to update its annual guidance throughout the year.&nbsp;

Health Care

General

InfuSystem Estimates 2025 With Net Revenue Growth Of 8% To 10%, With Adjusted EBITDA Margin To Be In The High-Teens

InfuSystems Holdings (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/INFU#AMEX">INFU</a>) reported quarterly earnings of $0.04 per share which missed the analyst consensus estimate of $0.07 by 42.86 percent. The company reported quarterly sales of $33.85 million which missed the analyst consensus estimate of $34.90 million by 3.02 percent. This is a 6.54 percent increase over sales of $31.77 million the same period last year.

InfuSystems Holdings Q4 2024 GAAP EPS $0.04 Misses $0.07 Estimate, Sales $33.85M Miss $34.90M Estimate

<h3>Companies Reporting Before The Bell</h3>
• 908 Devices (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MASS#NASDAQ">MASS</a>) is likely to report quarterly loss at $0.37 per share on revenue of $16.18 million. 
• Plug Power (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PLUG#NASDAQ">PLUG</a>) is projected to report quarterly loss at $0.23 per share on revenue of $262.65 million. 
• NexGen Energy (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NXE#NYSE">NXE</a>) is projected to report earnings for its fourth quarter. 
• EVgo (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EVGO#NASDAQ">EVGO</a>) is estimated to report quarterly loss at $0.09 per share on revenue of $69.00 million. 
• L.B. Foster (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FSTR#NASDAQ">FSTR</a>) is estimated to report quarterly earnings at $0.22 per share on revenue of $131.48 million. 
• WAVE Life Sciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WVE#NASDAQ">WVE</a>) is estimated to report quarterly loss at $0.24 per share on revenue of $25.59 million. 
• InfuSystems Holdings (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/INFU#AMEX">INFU</a>) is projected to report quarterly earnings at $0.08 per share on revenue of $34.40 million. 
• Amylyx Pharma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMLX#NASDAQ">AMLX</a>) is expected to report earnings for its fourth quarter. 
• Neuronetics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/STIM#NASDAQ">STIM</a>) is projected to report quarterly loss at $0.24 per share on revenue of $18.98 million. 
• Y-mAbs Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/YMAB#NASDAQ">YMAB</a>) is estimated to report quarterly loss at $0.12 per share on revenue of $26.94 million. 
• Olaplex Hldgs (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/OLPX#NASDAQ">OLPX</a>) is projected to report quarterly earnings at $0.01 per share on revenue of $87.51 million. 
• Hagerty (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HGTY#NYSE">HGTY</a>) is expected to report quarterly earnings at $0.01 per share on revenue of $279.58 million. 
• Angel Oak Mortgage REIT (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AOMR#NYSE">AOMR</a>) is expected to report quarterly earnings at $0.27 per share on revenue of $9.99 million. 
• Esperion Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ESPR#NASDAQ">ESPR</a>) is estimated to report quarterly loss at $0.13 per share on revenue of $63.06 million. 
• Sophia Genetics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SOPH#NASDAQ">SOPH</a>) is expected to report quarterly loss at $0.15 per share on revenue of $17.71 million. 
• Paysafe (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PSFE#NYSE">PSFE</a>) is projected to report quarterly earnings at $0.72 per share on revenue of $437.22 million. 
• Compugen (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CGEN#NASDAQ">CGEN</a>) is likely to report quarterly loss at $0.07 per share on revenue of $24.96 million. 
• Sea (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SE#NYSE">SE</a>) is expected to report quarterly earnings at $0.70 per share on revenue of $4.60 billion. 
• Genius Sports (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GENI#NYSE">GENI</a>) is estimated to report quarterly earnings at $0.07 per share on revenue of $175.71 million. 
• On Holding (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ONON#NYSE">ONON</a>) is expected to report quarterly earnings at $0.18 per share on revenue of $593.34 million. 
• Nayax (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NYAX#NASDAQ">NYAX</a>) is projected to report quarterly earnings at $0.10 per share on revenue of $91.89 million. 
• Best Buy Co (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BBY#NYSE">BBY</a>) is likely to report quarterly earnings at $2.42 per share on revenue of $13.69 billion. 
• Target (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TGT#NYSE">TGT</a>) is likely to report quarterly earnings at $2.65 per share on revenue of $30.28 billion. 
• CPI Card (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PMTS#NASDAQ">PMTS</a>) is estimated to report quarterly earnings at $0.57 per share on revenue of $118.97 million. 
• Wag Group (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PET#NASDAQ">PET</a>) is likely to report quarterly earnings at $0.40 per share on revenue of $290.88 million. 
• Modiv Industrial (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MDV#NYSE">MDV</a>) is expected to report quarterly earnings at $0.27 per share on revenue of $11.86 million. 
• AutoZone (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AZO#NYSE">AZO</a>) is estimated to report quarterly earnings at $29.90 per share on revenue of $4.00 billion. 
<h3>Companies Reporting After The Bell</h3>
• Medallion Finl (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MFIN#NASDAQ">MFIN</a>) is expected to report quarterly earnings at $0.33 per share on revenue of $53.66 million. 
• Southland Holdings (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/SLND#AMEX">SLND</a>) is projected to report quarterly loss at $0.49 per share on revenue of $230.13 million. 
• Gulf Island Fabrication (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GIFI#NASDAQ">GIFI</a>) is expected to report quarterly earnings at $0.12 per share on revenue of $41.00 million. 
• Cumberland (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CPIX#NASDAQ">CPIX</a>) is projected to report earnings for its fourth quarter. 
• Baytex Energy (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BTE#NYSE">BTE</a>) is estimated to report quarterly earnings at $0.16 per share on revenue of $980.40 million. 
• Stellus Cap Investment (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SCM#NYSE">SCM</a>) is estimated to report quarterly earnings at $0.39 per share on revenue of $26.54 million. 
• ChromaDex (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CDXC#NASDAQ">CDXC</a>) is estimated to report quarterly earnings at $0.02 per share on revenue of $26.52 million. 
• Rigel Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RIGL#NASDAQ">RIGL</a>) is expected to report quarterly earnings at $0.33 per share on revenue of $57.60 million. 
• Astronics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ATRO#NASDAQ">ATRO</a>) is likely to report quarterly earnings at $0.28 per share on revenue of $194.91 million. 
• Fuel Tech (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FTEK#NASDAQ">FTEK</a>) is expected to report quarterly loss at $0.03 per share on revenue of $5.63 million. 
• comScore (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SCOR#NASDAQ">SCOR</a>) is likely to report quarterly earnings at $0.36 per share on revenue of $91.66 million. 
• Alpha Teknova (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TKNO#NASDAQ">TKNO</a>) is estimated to report quarterly loss at $0.12 per share on revenue of $8.78 million. 
• Mayville Engineering (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MEC#NYSE">MEC</a>) is projected to report quarterly loss at $0.08 per share on revenue of $124.13 million. 
• NeuroPace (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NPCE#NASDAQ">NPCE</a>) is estimated to report quarterly loss at $0.24 per share on revenue of $21.11 million. 
• ATN International (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ATNI#NASDAQ">ATNI</a>) is projected to report quarterly loss at $0.19 per share on revenue of $179.11 million. 
• Stem (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/STEM#NYSE">STEM</a>) is projected to report quarterly loss at $0.16 per share on revenue of $49.37 million. 
• OrthoPediatrics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/KIDS#NASDAQ">KIDS</a>) is projected to report quarterly loss at $0.26 per share on revenue of $52.70 million. 
• Ascent Industries (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ACNT#NASDAQ">ACNT</a>) is expected to report earnings for its fourth quarter. 
• Ecopetrol (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/EC#NYSE">EC</a>) is estimated to report quarterly earnings at $0.41 per share on revenue of $7.68 billion. 
• Horizon Tech Finance (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HRZN#NASDAQ">HRZN</a>) is projected to report quarterly earnings at $0.32 per share on revenue of $25.68 million. 
• Owlet (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/OWLT#NYSE">OWLT</a>) is expected to report quarterly loss at $0.48 per share on revenue of $16.92 million. 
• AeroVironment (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AVAV#NASDAQ">AVAV</a>) is expected to report quarterly earnings at $0.86 per share on revenue of $214.00 million. 
• Ross Stores (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ROST#NASDAQ">ROST</a>) is estimated to report quarterly earnings at $1.67 per share on revenue of $5.95 billion. 
• Evolus (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EOLS#NASDAQ">EOLS</a>) is likely to report quarterly earnings at $0.00 per share on revenue of $77.23 million. 
• Eos Energy Enterprises (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EOSE#NASDAQ">EOSE</a>) is expected to report quarterly loss at $0.20 per share on revenue of $6.23 million. 
• CryoPort (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CYRX#NASDAQ">CYRX</a>) is expected to report quarterly loss at $0.31 per share on revenue of $58.79 million. 
• Ingram Micro Holding (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/INGM#NYSE">INGM</a>) is likely to report quarterly earnings at $0.90 per share on revenue of $13.22 billion. 
• ChargePoint Hldgs (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CHPT#NYSE">CHPT</a>) is likely to report quarterly loss at $0.07 per share on revenue of $100.97 million. 
• Credo Technology Group (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CRDO#NASDAQ">CRDO</a>) is estimated to report quarterly earnings at $0.18 per share on revenue of $120.31 million. 
• Crexendo (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CXDO#NASDAQ">CXDO</a>) is expected to report quarterly earnings at $0.05 per share on revenue of $15.64 million. 
• CrowdStrike Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CRWD#NASDAQ">CRWD</a>) is estimated to report quarterly earnings at $0.86 per share on revenue of $1.03 billion. 
• Ooma (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/OOMA#NYSE">OOMA</a>) is likely to report quarterly earnings at $0.16 per share on revenue of $64.70 million. 
• Custom Truck One Source (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CTOS#NYSE">CTOS</a>) is expected to report quarterly earnings at $0.05 per share on revenue of $539.81 million. 
• Cricut (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CRCT#NASDAQ">CRCT</a>) is expected to report quarterly earnings at $0.04 per share on revenue of $214.41 million. 
• Orion Gr Hldgs (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ORN#NYSE">ORN</a>) is estimated to report quarterly earnings at $0.19 per share on revenue of $272.70 million. 
• Latham Group (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SWIM#NASDAQ">SWIM</a>) is likely to report quarterly loss at $0.01 per share on revenue of $84.95 million. 
• Box (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BOX#NYSE">BOX</a>) is estimated to report quarterly earnings at $0.41 per share on revenue of $278.60 million. 
• Fabrinet (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FN#NYSE">FN</a>) is projected to report quarterly earnings at $0.91 per share on revenue of $223.23 million. 
• Weyco Group (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WEYS#NASDAQ">WEYS</a>) is projected to report earnings for its fourth quarter. 
• Sociedad Quimica Y Minera (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SQM#NYSE">SQM</a>) is likely to report quarterly earnings at $0.84 per share on revenue of $1.13 billion. 
• Nordstrom (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/JWN#NYSE">JWN</a>) is likely to report quarterly earnings at $0.90 per share on revenue of $4.33 billion. 
This article was generated by Benzinga's automated content engine and reviewed by an editor.

ACNT

AOMR

ATNI

ATRO

AVAV

CDXC

CGEN

CHPT

CPIX

CRCT

CRDO

CRWD

CTOS

CXDO

CYRX

EOLS

EOSE

ESPR

EVGO

FSTR

FTEK

GENI

GIFI

HGTY

HRZN

INGM

KIDS

MASS

MFIN

NPCE

Nuveen Arizona Dividend Advantage Municipal Funds 3

NYAX

OLPX

ONON

OOMA

OWLT

PLUG

PMTS

PSFE

RIGL

ROST

SCOR

SLND

SOPH

STEM

STIM

SWIM

TKNO

WEYS

YMAB

Earnings Scheduled For March 4, 2025

Full Year 2024 Guidance
InfuSystem is reaffirming its annual guidance for the full year 2024 with net revenue growth estimated to be in the high-single-digit range and forecasting Adjusted EBITDA margin (non-GAAP) to be in the high-teens, exceeding the Company's margin of 17.8% in 2023.

InfuSystem Reiterates Its 2024 Guidance Of Net Revenue Growth Expected To Be In The High-Single-Digit Range And Adjusted EBITDA To Be In The High-Teens

InfuSystems Holdings (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/INFU#AMEX">INFU</a>) reported quarterly earnings of $0.08 per share which beat the analyst consensus estimate of $0.06 by 33.33 percent. This is a 166.67 percent increase over earnings of $0.03 per share from the same period last year. The company reported quarterly sales of $35.320 million which beat the analyst consensus estimate of $34.483 million by 2.43 percent. This is a 10.69 percent increase over sales of $31.909 million the same period last year.

InfuSystems Holdings Q3 2024 GAAP EPS $0.08 Beats $0.06 Estimate, Sales $35.320M Beat $34.483M Estimate

B. Riley Securities initiates coverage on InfuSystems Holdings (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/INFU#AMEX">INFU</a>) with a Buy rating and announces Price Target of $13.

Price Target

Initiation

Analyst Ratings

B. Riley Securities Initiates Coverage On InfuSystems Holdings with Buy Rating, Announces Price Target of $13

Contracts

InfuSystem And Its Joint Venture Partner Sanara Medtech Executed An Exclusive United States Distribution Agreement With ChemoMouthpiece, Sanara Invested $5M For A 6.6% Ownership Position In ChemoMouthpiece

Full Year 2024&nbsp;Guidance
InfuSystem is reaffirming its annual&nbsp;guidance&nbsp;for the full year 2024 with net revenue growth estimated to be in the high-single-digit range and forecasting Adjusted EBITDA margin (non-GAAP) to be in the high-teens, exceeding the Company&#39;s margin of&nbsp;17.8%&nbsp;in 2023.

InfuSystem Reaffirms Its 2024 Guidance Of Net Revenue Growth Expeted To Be In The High-Single-Digit Range And Adjusted EBITDA To Be In The High-Teens

InfuSystems Holdings (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/INFU#AMEX">INFU</a>) reported quarterly earnings of $0.03 per share which missed the analyst consensus estimate of $0.04 by 25 percent. This is a 50 percent increase over earnings of $0.02 per share from the same period last year. The company reported quarterly sales of $33.698 million which beat the analyst consensus estimate of $33.252 million by 1.34 percent. This is a 6.19 percent increase over sales of $31.735 million the same period last year.

Earnings Misses

InfuSystems Holdings Q2 2024 GAAP EPS $0.03 Misses $0.04 Estimate, Sales $33.698M Beat $33.252M Estimate

InfuSystem Inks Three-Year Distribution Deal With Smith+Nephew For Its Negative Pressure Wound Therapy System And Supplies

A substantial acquisition of company stock options by Scott Shuda, Board Member at InfuSystems Holdings (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/INFU#AMEX">INFU</a>) was reported on May 21, based on a new SEC filing.
What Happened: In a Form 4 filing with the <a href="https://www.sec.gov/Archives/edgar/data/0001337013/000162828024024589//Archives/edgar/data/1337013/000162828024024589/0001628280-24-024589-index.htm">U.S. Securities and Exchange Commission</a> on Tuesday, Shuda, Board Member at InfuSystems Holdings, acquired stock options for 35,685 shares of INFU. These options provide Shuda with the right to purchase the company's stock at $6.34 per share.
InfuSystems Holdings shares are currently trading up by 0.6%, with a current price of $6.67 as of Wednesday morning. This brings the total value of Shuda's 35,685 shares to $11,776.
<h3>About InfuSystems Holdings</h3>
InfuSystems Holdings Inc is a health care service provider, facilitating outpatient care for durable medical equipment manufacturers and health care providers. INFU services are provided under a two-platform model. The first platform is Patient Services, providing the last-mile solution for clinic-to-home healthcare where the continuing treatment involves complex durable medical equipment and services. The Patient segment is comprised of Oncology, Pain Management and Wound Therapy businesses. The second platform, Device Solutions, supports the Patient Services platform and leverages strong service orientation to win incremental business from its direct payer clients. The Device segment is comprised of direct payer rentals, pump and consumable sales, and biomedical services and repair.
<h3>InfuSystems Holdings's Financial Performance</h3>
Revenue Growth: InfuSystems Holdings displayed positive results in 3 months. As of 31 March, 2024, the company achieved a solid revenue growth rate of approximately 5.35%. This indicates a notable increase in the company's top-line earnings. When compared to others in the Health Care sector, the company faces challenges, achieving a growth rate lower than the average among peers.
Navigating Financial Profits:
<ul>
<li>
Gross Margin: Achieving a high gross margin of 51.49%, the company performs well in terms of cost management and profitability within its sector.
</li>
<li>
Earnings per Share (EPS): InfuSystems Holdings's EPS reflects a decline, falling below the industry average with a current EPS of -0.05.
</li>
</ul>
Debt Management: The company faces challenges in debt management with a debt-to-equity ratio higher than the industry average. With a ratio of 0.67, caution is advised due to increased financial risk.
In-Depth Valuation Examination:
<ul>
<li>
Price to Earnings (P/E) Ratio: InfuSystems Holdings's stock is currently priced at a premium level, as reflected in the higher-than-average P/E ratio of 663.0.
</li>
<li>
Price to Sales (P/S) Ratio: The current P/S ratio of 1.13 is above industry norms, reflecting an elevated valuation for InfuSystems Holdings's stock and potential overvaluation based on sales performance.
</li>
<li>
EV/EBITDA Analysis (Enterprise Value to its Earnings Before Interest, Taxes, Depreciation &amp; Amortization): The company's EV/EBITDA ratio 11.31 is above the industry average, suggesting that the market values the company more highly for each unit of EBITDA. This could be attributed to factors such as strong growth prospects or superior operational efficiency.
</li>
</ul>
Market Capitalization: Indicating a reduced size compared to industry averages, the company's market capitalization poses unique challenges.
<a href="https://www.schwab.com/brokerage?aff=XEC">Now trade stocks online commission free with Charles Schwab, a trusted and complete investment firm.</a>
<h3>The Impact of Insider Transactions on Investments</h3>
Insider transactions should be considered alongside other factors when making investment decisions, as they can offer important insights.
In the context of legal matters, the term "insider" refers to any officer, director, or beneficial owner holding more than ten percent of a company's equity securities, as outlined by Section 12 of the Securities Exchange Act of 1934. This includes executives in the c-suite and significant hedge funds. Such insiders are obligated to report their transactions through a Form 4 filing, which must be completed within two business days of the transaction.
Pointing towards optimism, a company insider's new purchase signals their positive anticipation for the stock to rise.
Despite insider sells not always signaling a bearish sentiment, they can be driven by various factors.
<h3>Navigating the World of Insider Transaction Codes</h3>
When it comes to transactions, <a href="https://www.benzinga.com/money/investing-tools">investors</a> tend to focus on those in the open market, detailed in Table I of the Form 4 filing. A P in Box 3 denotes a purchase, while S indicates a sale. Transaction code C signals the conversion of an option, and transaction code A denotes a grant, award, or other acquisition of securities from the company.
<a href="https://www.benzinga.com/sec/insider-trades/search/index?company_cik=0001337013">Check Out The Full List Of InfuSystems Holdings's Insider Trades.</a>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Scott Shuda Makes A Tactical Move: Adds InfuSystems Holdings Stock Options To Portfolio

Paul A. Gendron, Director at InfuSystems Holdings (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/INFU#AMEX">INFU</a>), reported acquisition of company stock options on May 21, according to a new SEC filing.
What Happened: Uncovered in a Form 4 filing on Tuesday with the <a href="https://www.sec.gov/Archives/edgar/data/0001337013/000162828024024587//Archives/edgar/data/1337013/000162828024024587/0001628280-24-024587-index.htm">U.S. Securities and Exchange Commission</a>, Gendron, Director at InfuSystems Holdings, executed an insider options move. This move consisted of acquiring stock options for 35,685 shares of INFU, granting Gendron the right to purchase the company's stock at an exercise price of $6.34 per share.
InfuSystems Holdings shares are currently trading up by 0.6%, with a current price of $6.67 as of Wednesday morning. This brings the total value of Gendron's 35,685 shares to $11,776.
<h3>Get to Know InfuSystems Holdings Better</h3>
InfuSystems Holdings Inc is a health care service provider, facilitating outpatient care for durable medical equipment manufacturers and health care providers. INFU services are provided under a two-platform model. The first platform is Patient Services, providing the last-mile solution for clinic-to-home healthcare where the continuing treatment involves complex durable medical equipment and services. The Patient segment is comprised of Oncology, Pain Management and Wound Therapy businesses. The second platform, Device Solutions, supports the Patient Services platform and leverages strong service orientation to win incremental business from its direct payer clients. The Device segment is comprised of direct payer rentals, pump and consumable sales, and biomedical services and repair.
<h3>Breaking Down InfuSystems Holdings's Financial Performance</h3>
Revenue Growth: Over the 3 months period, InfuSystems Holdings showcased positive performance, achieving a revenue growth rate of 5.35% as of 31 March, 2024. This reflects a substantial increase in the company's top-line earnings. In comparison to its industry peers, the company trails behind with a growth rate lower than the average among peers in the Health Care sector.
Navigating Financial Profits:
<ul>
<li>
Gross Margin: Achieving a high gross margin of 51.49%, the company performs well in terms of cost management and profitability within its sector.
</li>
<li>
Earnings per Share (EPS): InfuSystems Holdings's EPS is below the industry average, signaling challenges in bottom-line performance with a current EPS of -0.05.
</li>
</ul>
Debt Management: With a high debt-to-equity ratio of 0.67, InfuSystems Holdings faces challenges in effectively managing its debt levels, indicating potential financial strain.
Evaluating Valuation:
<ul>
<li>
Price to Earnings (P/E) Ratio: InfuSystems Holdings's stock is currently priced at a premium level, as reflected in the higher-than-average P/E ratio of 663.0.
</li>
<li>
Price to Sales (P/S) Ratio: With a higher-than-average P/S ratio of 1.13, InfuSystems Holdings's stock is perceived as being overvalued in the market, particularly in relation to sales performance.
</li>
<li>
EV/EBITDA Analysis (Enterprise Value to its Earnings Before Interest, Taxes, Depreciation &amp; Amortization): InfuSystems Holdings's EV/EBITDA ratio, surpassing industry averages at 11.31, positions it with an above-average valuation in the market.
</li>
</ul>
Market Capitalization Analysis: Below industry benchmarks, the company's market capitalization reflects a smaller scale relative to peers. This could be attributed to factors such as growth expectations or operational capacity.
<a href="https://www.schwab.com/brokerage?aff=XEC">Now trade stocks online commission free with Charles Schwab, a trusted and complete investment firm.</a>
<h3>The Impact of Insider Transactions on Investments</h3>
It's important to note that insider transactions alone should not dictate investment decisions, but they can provide valuable insights.
Considering the legal perspective, an "insider" is defined as any officer, director, or beneficial owner holding more than ten percent of a company's equity securities, according to Section 12 of the Securities Exchange Act of 1934. This includes executives in the c-suite and major hedge funds. These insiders are mandated to disclose their transactions through a Form 4 filing, to be submitted within two business days of the transaction.
Pointing towards optimism, a company insider's new purchase signals their positive anticipation for the stock to rise.
Nevertheless, insider sells may not necessarily indicate a bearish view and can be influenced by various factors.
<h3>Important Transaction Codes</h3>
For <a href="https://www.benzinga.com/money/investing-tools">investors</a>, a primary focus lies on transactions occurring in the open market, as indicated in Table I of the Form 4 filing. A P in Box 3 denotes a purchase, while S signifies a sale. Transaction code C signals the conversion of an option, and transaction code A denotes a grant, award, or other acquisition of securities from the company.
<a href="https://www.benzinga.com/sec/insider-trades/search/index?company_cik=0001337013">Check Out The Full List Of InfuSystems Holdings's Insider Trades.</a>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Paul A. Gendron At InfuSystems Holdings Acquires Stock Options

A substantial acquisition of company stock options by Ralph F. Boyd, Jr., Director at InfuSystems Holdings (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/INFU#AMEX">INFU</a>) was reported on May 21, based on a new SEC filing.
What Happened: In a Form 4 filing with the <a href="https://www.sec.gov/Archives/edgar/data/0001337013/000162828024024609//Archives/edgar/data/1337013/000162828024024609/0001628280-24-024609-index.htm">U.S. Securities and Exchange Commission</a> on Tuesday, Jr., Director at InfuSystems Holdings, acquired stock options for 35,685 shares of INFU. These options provide Jr. with the right to purchase the company's stock at $6.34 per share.
Currently, InfuSystems Holdings shares are trading up 0.6%, priced at $6.67 during Wednesday's morning. This values Jr.'s 35,685 shares at $11,776.
<h3>All You Need to Know About InfuSystems Holdings</h3>
InfuSystems Holdings Inc is a health care service provider, facilitating outpatient care for durable medical equipment manufacturers and health care providers. INFU services are provided under a two-platform model. The first platform is Patient Services, providing the last-mile solution for clinic-to-home healthcare where the continuing treatment involves complex durable medical equipment and services. The Patient segment is comprised of Oncology, Pain Management and Wound Therapy businesses. The second platform, Device Solutions, supports the Patient Services platform and leverages strong service orientation to win incremental business from its direct payer clients. The Device segment is comprised of direct payer rentals, pump and consumable sales, and biomedical services and repair.
<h3>Understanding the Numbers: InfuSystems Holdings's Finances</h3>
Revenue Growth: InfuSystems Holdings's revenue growth over a period of 3 months has been noteworthy. As of 31 March, 2024, the company achieved a revenue growth rate of approximately 5.35%. This indicates a substantial increase in the company's top-line earnings. In comparison to its industry peers, the company trails behind with a growth rate lower than the average among peers in the Health Care sector.
Analyzing Profitability Metrics:
<ul>
<li>
Gross Margin: Achieving a high gross margin of 51.49%, the company performs well in terms of cost management and profitability within its sector.
</li>
<li>
Earnings per Share (EPS): InfuSystems Holdings's EPS is below the industry average, signaling challenges in bottom-line performance with a current EPS of -0.05.
</li>
</ul>
Debt Management: InfuSystems Holdings's debt-to-equity ratio is notably higher than the industry average. With a ratio of 0.67, the company relies more heavily on borrowed funds, indicating a higher level of financial risk.
Navigating Market Valuation:
<ul>
<li>
Price to Earnings (P/E) Ratio: The current Price to Earnings ratio of 663.0 is higher than the industry average, indicating the stock is priced at a premium level according to the market sentiment.
</li>
<li>
Price to Sales (P/S) Ratio: With a relatively high Price to Sales ratio of 1.13 as compared to the industry average, the stock might be considered overvalued based on sales performance.
</li>
<li>
EV/EBITDA Analysis (Enterprise Value to its Earnings Before Interest, Taxes, Depreciation &amp; Amortization): InfuSystems Holdings's EV/EBITDA ratio, surpassing industry averages at 11.31, positions it with an above-average valuation in the market.
</li>
</ul>
Market Capitalization Perspectives: The company's market capitalization falls below industry averages, signaling a relatively smaller size compared to peers. This positioning may be influenced by factors such as perceived growth potential or operational scale.
<a href="https://www.schwab.com/brokerage?aff=XEC">Now trade stocks online commission free with Charles Schwab, a trusted and complete investment firm.</a>
<h3>The Importance of Insider Transactions</h3>
Insider transactions are not the sole determinant of investment choices, but they are a factor worth considering.
In the context of legal matters, the term "insider" refers to any officer, director, or beneficial owner holding more than ten percent of a company's equity securities, as outlined by Section 12 of the Securities Exchange Act of 1934. This includes executives in the c-suite and significant hedge funds. Such insiders are obligated to report their transactions through a Form 4 filing, which must be completed within two business days of the transaction.
Pointing towards optimism, a company insider's new purchase signals their positive anticipation for the stock to rise.
Despite insider sells not always signaling a bearish sentiment, they can be driven by various factors.
<h3>Essential Transaction Codes Unveiled</h3>
For <a href="https://www.benzinga.com/money/investing-tools">investors</a>, a primary focus lies on transactions occurring in the open market, as indicated in Table I of the Form 4 filing. A P in Box 3 denotes a purchase, while S signifies a sale. Transaction code C signals the conversion of an option, and transaction code A denotes a grant, award, or other acquisition of securities from the company.
<a href="https://www.benzinga.com/sec/insider-trades/search/index?company_cik=0001337013">Check Out The Full List Of InfuSystems Holdings's Insider Trades.</a>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Strategic Move: Ralph F. Boyd, Jr. Enhances Portfolio With InfuSystems Holdings Stock Options

WIIM

InfuSystems shares are trading higher after the company announced a $20 million stock buyback program.

Press Releases

InfuSystem to Participate in Lytham Partners Fall 2024 Investor Conference on October 1, 2024

InfuSystem to Report Third Quarter 2024 Financial Results on November 7, 2024

InfuSystem Reports Third Quarter 2024 Financial Results

InfuSystem Appoints Ronald Hundzinski to the Board of Directors

InfuSystem to Present at Sidoti Small Cap Conference on December 4, 2024

InfuSystem to Report Fourth Quarter and Full Year 2024 Financial Results on March 4, 2025

InfuSystem Announces Operational and Financial Results for Fourth Quarter and Full Year 2024

InfuSystem Announces CEO Transition; Carrie Lachance to Become Chief Executive Officer

Comments

InfuSystems Holdings

Vendite allo scoperto

InfuSystems Holdings (AMEX:INFU) Azioni, Report sulle vendite allo scoperto

Le persone guardano anche

Notizie

PARTNER/COLLABORATORE

BENZINGA NEL MONDO